Sandeep Gurbuxani to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications Sandeep Gurbuxani has written about Antibodies, Monoclonal, Humanized.
Connection Strength
0.058
-
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study. JAMA Oncol. 2022 09 01; 8(9):1278-1286.
Score: 0.035
-
CHOP plus alemtuzumab can induce metabolic response by FDG-PET but has minimal long-term benefits: a case report and literature review. J Gastrointest Cancer. 2007; 38(1):19-23.
Score: 0.012
-
CHOP plus alemtuzumab can induce metabolic response by FDG-PET but has minimal long-term benefits: a case report and literature review. J Gastrointest Cancer. 2007; 38(1):59-62.
Score: 0.012